603456 Zhejiang Jiuzhou Pharmaceutical
- 15.60
- +0.49+3.24%
Zhejiang Jiuzhou Pharmaceutical News
Minsheng Securities released a research report on April 25 stating that it gave Jiuzhou Pharmaceutical (603456.SH) a recommended rating. The main reasons for the rating include: 1) Noxintol's global sales increased rapidly in the first quarter, and CDMO o
Minsheng Securities released a research report on April 25 stating that it gave Jiuzhou Pharmaceutical (603456.SH) a recommended rating. The main reasons for the rating include: 1) Noxintol's global sales increased rapidly in the first quarter, and CDMO orders increased steadily; 2) emerging businesses such as peptides and small nucleic acids grew rapidly, and the strategic layout of overseas CRO platforms increased customer stickiness. (Mainichi Keizai Shimbun)
Express News | Jiuzhou Pharmaceutical: Net profit attributable to mother in the first quarter was 237 million yuan, down 15.65% year on year
Jiuzhou Pharmaceutical (603456): CDMO is tough under short-term pressure in the API business
Revenue and profit were simultaneously pressured by the API business company on April 24. 1Q24 results: 1Q24 revenue/net profit attributable to mother/net profit deducted from non-net profit were 1,476/2.37/234 million yuan, respectively (-16/-
Jiuzhou Pharmaceutical (603456) 2023 Report Review: Annual Revenue and Profit Growth Slows Down, CDMO Business Achieves High-Quality Growth
Announcement: Jiuzhou Pharmaceutical released its 2023 annual report. Comment: Revenue side growth is slowing down. In 2023, the company's revenue was 5.523 billion yuan, up 1.44% year on year; net profit to mother was 1,033 billion yuan, up 12 years on year
Jiuzhou Pharmaceutical (603456): Annual revenue and profit growth slowed, CDMO business achieved high-quality growth
Announcement: Jiuzhou Pharmaceutical released its 2023 annual report. Comment: Revenue side growth is slowing down. In 2023, the company's revenue was 5.523 billion yuan, up 1.44% year on year; net profit to mother was 1,033 billion yuan, up 12 years on year
Southwest Securities released a research report on April 16 stating that it gave Jiuzhou Pharmaceutical (603456.SH) a purchase rating. The main reasons for the rating include: 1) the performance was in line with expectations, and the CDMO sector achieved
Southwest Securities released a research report on April 16 stating that it gave Jiuzhou Pharmaceutical (603456.SH) a purchase rating. The main reasons for the rating include: 1) the performance was in line with expectations, and the CDMO sector achieved steady growth; 2) capacity building for new businesses such as peptides, conjugated drugs, and formulation platforms is beginning to bear fruit. (Mainichi Keizai Shimbun)
Jiuzhou Pharmaceutical (603456.SH): Japanese CRO mainly focuses on innovative drug CMC business
Gelonghui, April 16 | Jiuzhou Pharmaceutical (603456.SH) said on the investor interactive platform that Japan's CRO company mainly focuses on innovative drug CMC business and is expected to be put into use in the third quarter of 2024.
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) Analysts Just Slashed This Year's Estimates
The analysts covering Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for thi
Jiuzhou Pharmaceutical (603456): CDMO business is growing steadily, APIs are under pressure in the short term
Incident: The company announced its 2023 annual report. In 2023, it achieved operating income of 5.523 billion yuan (+1.44%), net profit to mother of 1,033 billion yuan (+12.17%), net profit not attributable to mother of 10.2 billion yuan
Jiuzhou Pharmaceutical (603456): CDMO is growing steadily and the API business is under pressure in the short term
Core idea The company's CDMO sector achieved steady growth of 19.4% in 2023, the number of pipeline projects continued to increase, and the number of commercialized projects reached 32. Although the API sector was under pressure in the short term due to increased competition in the industry, the company accelerated its push
Express News | Jiuzhou Pharmaceutical: Looking at orders in hand, the peptide business is expected to increase by more than 30% in 2024 compared to last year
Jiuzhou Pharmaceutical (603456): CDMO business grows steadily and continues to lay out new businesses
Incident: The company released its 2023 annual report. In 2023, it achieved revenue of 5.523 billion yuan, an increase of 1.44% year on year; net profit to mother was 1,033 billion yuan, up 12.17% year on year; net profit without return to mother 10.
Great Wall Guorui Securities released a research report on April 9 stating that it gave Jiuzhou Pharmaceutical (603456.SH) a purchase rating. The main reasons for the rating include: 1) Profitability has increased, putting pressure on the API business; 2)
Great Wall Guorui Securities released a research report on April 9 stating that it gave Jiuzhou Pharmaceutical (603456.SH) a purchase rating. The main reasons for the rating include: 1) Profitability has increased, putting pressure on the API business; 2) the CDMO business has maintained a rapid growth trend; and 3) the peptide and conjugation business is progressing smoothly. (Mainichi Keizai Shimbun)
Minsheng Securities released a research report on April 9 stating that it gave Jiuzhou Pharmaceutical (603456.SH) a recommended rating. The main reasons for the rating include: 1) the rapid expansion of CDMO business for APIs and formulations, and a stead
Minsheng Securities released a research report on April 9 stating that it gave Jiuzhou Pharmaceutical (603456.SH) a recommended rating. The main reasons for the rating include: 1) the rapid expansion of CDMO business for APIs and formulations, and a steady increase in project revenue during the commercialization phase; 2) layout of specialty platforms for peptides, conjugated drugs, and small nucleic acids to successfully complete multiple project delivery tasks; 3) comprehensively improving advanced production capacity for APIs, CDMOs, peptides and formulations, and continuously strengthening global business acceptance capabilities. (Mainichi Keizai Shimbun)
Jiuzhou Pharmaceutical (603456): CDMO's steady growth puts pressure on the API sector
The 2023 results are lower than our expectations. The company announced the 2023 results: revenue of 5.523 billion yuan, up 1.4% year on year; net profit to mother of 1,033 billion yuan, up 12.2% year on year; minus 10.2 percent year on year
Jiuzhou Pharmaceutical (603456) Annual Report Review Report: Revenue is basically in line with expectations. The CDMO sector maintains high growth and the project pipeline continues to be rich
The company released its 2023 annual report. For the full year of 2023, the company achieved operating income of 5.52 billion yuan, an increase of 1.4% over the previous year; achieved net profit of 1.03 billion yuan, an increase of 12.2% over the previous year; net profit after deducting the mother
Jiuzhou Pharmaceutical (603456): CDMO is resilient and waits for peak rotation
Profitability increased throughout the year, and Q4 short-term pressure was placed on April 8. The company announced its 2023 full-year results: achieving revenue/net profit to mother/net profit deducted from non-net profit of 5,55.23/10.33/1,024 billion yuan in 2023 (
Yao Ming Kangde's decline extended to 2%, and the stock price hit a new low since August 2019. The CRO concept generally declined, with Jiuzhou Pharmaceutical falling more than 8%, and Gloria & Sannuo Biotech falling more than 3%.
Yao Ming Kangde's decline extended to 2%, and the stock price hit a new low since August 2019. The CRO concept generally declined, with Jiuzhou Pharmaceutical falling more than 8%, and Gloria & Sannuo Biotech falling more than 3%.
Jiuzhou Pharmaceutical (603456): Performance showed steady growth and the API business was under pressure
Incident Overview Company Announces 2023 Annual Report: 23 Achieved operating income of 5.523 billion yuan for the full year, an increase of 1.44% over the previous year, and realized net profit of 1,033 billion yuan, an increase of 12.17% over the previous year, and realized the deduction of non-net profit
Jiuzhou Pharmaceutical (603456) 2023 Annual Report Review: CDMO Commercialization Revenue Steady Increase and Continues to Build Advanced Global Production Capacity
Event: On April 8, 2024, Jiuzhou Pharmaceutical released its 2023 annual report. The company achieved annual revenue of 5,523 billion yuan, an increase of 1.44% over the previous year; net profit to mother was 1,033 billion yuan, an increase of 12 billion yuan over the previous year
Analysis
Price Target
No Data
